Please ensure Javascript is enabled for purposes of website accessibility

What You Need to Know About Sangamo Therapeutics' Q1 Earnings Results

By Keith Speights – May 8, 2019 at 9:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's revenue fell. But it still managed to beat the consensus Wall Street earnings estimate.

Sangamo Therapeutics (SGMO -1.79%) beat Wall Street estimates when it announced its fourth-quarter results in February. Revenue jumped by 105% year over year, and the biotech's net loss wasn't as bad as analysts expected.

Investors learned how Sangamo performed in the first quarter on Wednesday with the company providing a quarterly update after the market closed. How did the biotech fare? Here's what you need to know about Sangamo's Q1 results.

Health care professionals looking at a slide

Image source: Getty Images.

By the numbers

Sangamo's top-line performance went in the wrong direction in the first quarter. Revenue fell nearly 36% year over year to $8.1 million. The consensus analysts' estimate projected that the company's Q1 revenue would top $22.8 million.

The company announced a GAAP net loss of $42.2 million, or $0.41 per share, in the first quarter. This reflected deterioration from Sangamo's net loss of $20.2 million, or $0.23 per share, reported in the same quarter of 2018. Analysts expected a net loss of $0.25 per share.

Sangamo ended the first quarter with cash, cash equivalents, and short-term investments of $351.6 million. The company had $400.5 million on hand as of March 31.

Behind the numbers

Sangamo's Q1 revenue decline was mainly due to changes in agreements with its big partners. Roughly $10.6 million of the revenue decline stemmed from a change in its hemophilia A collaboration with Pfizer. Another $2.4 million of the revenue decline related to Sangamo's agreement with Sanofi. However, these declines were partially offset by the company's agreement with Gilead Sciences' Kite Pharma unit, which added $8.3 million in revenue in the first quarter.

The company still managed to slightly beat the consensus Wall Street bottom-line estimate, though, despite the falling revenue. Sangamo anticipated that operating expenses would increase. They did increase, but not as much as analysts expected. Operating expenses rose 55% year over year to $52 million. This increase was due to Sangamo's acquisition of TxCell, higher staffing to support its preclinical and clinical development programs, and manufacturing-related activities.

What these numbers don't reflect, however, was Sangamo's pipeline progress after the first quarter ended. In April, the company announced promising results from a phase 1/2 clinical study evaluating experimental gene therapy SB-525 in treating patients with severe hemophilia A. Sangamo is partnering with Pfizer on SB-525.

Looking ahead

Sangoma expects that operating expenses for full-year 2019 will be between $210 million and $220 million. The company also projects that its current cash stockpile will carry it through the end of 2021.

With plenty of cash to fund operations, the main things for investors to watch will be Sangamo's clinical studies. The most important of these is the ongoing phase 1/2 study of SB-525. If all goes well, Sangamo and Pfizer could be headed toward a pivotal study of the experimental gene therapy.

Keith Speights owns shares of Gilead Sciences and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
$4.95 (-1.79%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.